NHS weight-loss medication: access routes and eligibility in 2026
There is no single UK queue for weight-loss medicines. Your route depends on the reason for treatment, where you live, clinical suitability and the service commissioned locally. In England, the current primary-care Mounjaro rollout is narrower than its medicine licence—and differs from specialist access.
Access information checked 19 September 2026. This guide explains routes; it does not decide whether you qualify. A self-entered BMI and a generic count of health conditions cannot safely make that decision.
Separate three questions before chasing a prescription
- Is it clinically appropriate? The prescriber assesses the actual medicine, indication, history and risks.
- Is that use funded through this NHS pathway? A licensed use is not automatically funded for everyone who meets the licence.
- Which local service provides it? The answer may be a commissioned primary-care service or a specialist team, not necessarily your own practice.
NHS England distinguishes specialist eligibility from phased primary-care access and permits different local delivery models. [1]
Mounjaro in England: what changed in June 2026?
From 23 June 2026, the primary-care rollout includes the second priority cohort as well as the first. NHS Cheshire and Merseyside describes the threshold as BMI at least 35 with at least four of five specified conditions, with lower BMI thresholds for named ethnic backgrounds. This is not simply “BMI 35 plus any four diagnoses”. [2]
| Phase | BMI before ethnicity adjustment | Qualifying conditions |
|---|---|---|
| Cohort I—continues | 40 or more | At least four of the five named conditions |
| Cohort II—from 23 June 2026 | 35–39.9 | At least four of the five named conditions |
| Cohort III—scheduled from 1 April 2027, not yet the current phase | 40 or more | Three of the five named conditions |
The five are hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease within the commissioning definition, and type 2 diabetes. The clinical definitions matter: for example, the sleep-apnoea criterion is not merely snoring. A clinician checks the diagnoses and applicable treatment criteria. [1]
The stated BMI thresholds are usually reduced by 2.5 for South Asian, Chinese, other Asian, Middle Eastern, Black African and African-Caribbean backgrounds. Ask the service to confirm how the adjustment applies to you. [2]
Specialist access is not the same as the primary-care phase
The wider specialist tirzepatide population described by NHS England has BMI at least 35 plus at least one weight-related condition, with the specified ethnicity adjustment and prescribing assessment. Services can prioritise referrals according to clinical need and capacity. Missing the current primary-care cohort therefore does not, by itself, answer whether a specialist referral is appropriate. [1]
Ask which pathway was considered, who accepts the referral and what happens while you wait. A funding rule is not a promise of an immediate appointment or a particular medicine.
The medicine name alone does not identify the pathway
Semaglutide (Wegovy): obesity prescribing through specialist weight-management services has its own criteria. There is also a distinct cardiovascular-risk indication for some people with established cardiovascular disease and overweight or obesity. Do not use the Mounjaro obesity cohort table to decide eligibility for that separate indication; ask the GP or cardiac team about the currently commissioned route. [3] [4] [5]
Liraglutide (Saxenda): NHS weight-loss access is through specialist services and is not a routine promise of a GP prescription. [6]
Orlistat: a different, meal-related medicine, available on prescription and in lower-dose pharmacy products. Discuss whether it fits your history and daily routine rather than treating it as an interchangeable injection substitute. [7]
Type 2 diabetes: tirzepatide prescribed for blood-glucose management has a separate eligibility pathway from tirzepatide for obesity. Ask which indication is being assessed. [1]
Outside England: use your own nation’s route
England’s phased table must not be presented as a UK-wide entitlement. Wales has a separate clinical pathway and health-board arrangements. Northern Ireland announced a first-phase obesity management service on 29 June 2026, with implementation expected in early autumn; an announcement is not evidence that every local referral route is already open. [8] [9]
In Scotland, ask your GP or NHS board which current weight-management service and formulary apply. In Wales, contact your health board; in Northern Ireland, your GP or HSC trust. Get the local route in writing when national headlines and practice information do not seem to match.
“Not available” can mean three very different things
| Answer you receive | Useful follow-up |
|---|---|
| Not clinically suitable | What makes it unsuitable, and what alternatives address the same health need? |
| Outside the current funded cohort | Which indication and care setting were assessed? Is a specialist referral appropriate? |
| Local pathway or capacity restriction | Who commissions the service, how are referrals handled and how can I check for a change? |
A clear explanation is more useful than repeatedly asking for the same brand. Request the local integrated care board’s pathway in England, or your national/local equivalent elsewhere. Keep the response and any referral details.
A practical appointment checklist—not a self-diagnosis finder
Bring your current medicines, known diagnoses, previous weight-management support, any private treatment and the dates of relevant reviews. You do not need to invent a perfect history or start a medicine privately to justify asking for help.
- Which clinical indication and NHS pathway are relevant to me?
- Am I being assessed against primary-care prioritisation or specialist referral criteria?
- What eating, activity and behavioural support comes with treatment?
- What happens if I am unsuitable, outside the current cohort or waiting for capacity?
- Who is responsible for monitoring, side effects and the next review?
Support, waiting and private-to-NHS handover
Ask for the support available now, not just the prescription you hope might follow. Keep mental health, sleep, eating difficulties and mobility in the conversation. A treatment decision should not reduce the appointment to a single BMI number.
Do not assume an NHS service will take over a privately started medicine, match its dose or refund its cost. Ask the receiving service before making financial or treatment plans. Share the exact product and treatment history; leave any switch to the prescribing team.
My Timber can hold your own goals and treatment/provider history so you do not have to reconstruct them for each conversation. It cannot verify NHS eligibility, advance a waiting list or replace the NHS service’s records. Open My Timber · Use the Programme’s everyday support.
Common questions
Can my GP prescribe Mounjaro for weight loss now?
In England, prescribing depends on clinical assessment and the currently commissioned primary-care or specialist route. The June 2026 rollout is not access for everyone who meets the medicine licence.
Does one weight-related condition qualify me?
It is not enough for the current England primary-care priority cohorts described here. The specialist pathway has different criteria; ask which setting is appropriate rather than treating the primary-care table as the only route.
Can I use the same criteria in Scotland, Wales or Northern Ireland?
No. The detailed phased table on this page describes England. Confirm your own nation’s and local service’s arrangements.
Sources and editorial responsibility
- NHS England: interim tirzepatide commissioning guidance, April 2026
- NHS Cheshire and Merseyside: Mounjaro phased access and dates
- NHS England: weight-management injections
- NHS: semaglutide uses and prescribing information
- NHS North East and North Cumbria: May/July 2026 prescribing decisions
- NHS: liraglutide
- NHS: orlistat
- Welsh Government: obesity clinical pathway, updated July 2026
- Department of Health Northern Ireland: first-phase service announcement, 29 June 2026
Product information and access arrangements can change. Use the original source and your treating service for decisions about your care. How SHIFT prepares articles · Report a factual correction.
What changed on 19 September 2026: Updated the June 2026 England rollout, separated specialist, diabetes and cardiovascular indications and UK nations, and replaced the generic eligibility finder with an appointment checklist.